TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Brief Summary: An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1-2 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 2-4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1-2 mg, Cariprazine 2-4.5 mg
B: Arm Label: Vilazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilazodone | Arm Label: Citalopram; Type: PLACEBO_COMPARATOR; Interventions: Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram
C: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): N/A
D: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Serum 25-hydroxy Vitamin D [25(OH)D] Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants
Brief Summary: This study will determine levels of vitamin D supplementation to achieve goal serum 25-hydroxy vitamin D \[25(OH)D\] levels of 30 ng/mL, and to define serum 25(OH)D levels required to achieve suppression of parathyroid hormone in preterm newborn infants hospitalized in Newborn Intensive Care Nursery (NICU). Infants 23 weeks gestational age or greater will be randomized to two different levels of vitamin D supplementation: 400 IU vitamin D3/day, or 800 IU vitamin D3/day.


Options:
A: Arm Label: 400 IU/day vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferal | Arm Label: 800 IU/day vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferal; Assigned to Arm(s): 400 IU/day vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): 800 IU/day vitamin D3
B: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group
C: Arm Label: Atopic dermatitis patients: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral vitamin D | Arm Label: Atopic dermatitis patients: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral vitamin D; Assigned to Arm(s): Atopic dermatitis patients: Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atopic dermatitis patients: Placebo
D: Arm Label: Vitamin D supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 10 ug/day | Arm Label: Vitamin D supplement at 30 ug/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 30 ug/day; Assigned to Arm(s): Vitamin D supplement at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 10 ug/day; Assigned to Arm(s): Vitamin D supplement

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Healthy Weight for Life Program
Brief Summary: This study is a randomized controlled pilot of a work site weight control intervention. The purpose of the pilot is to obtain preliminary data for future NIH submissions. Four work sites were identified through a multistage recruiting process. Work sites were randomized to either the intervention group, which will receive the intervention immediately following randomization or the control group which will receive a shortened intervention over a 1-month period, 6 months after the active intervention sites have completed their program. The intervention will consist of a variety of activities conducted over a 6 month period, that are overseen by a work site-Tufts oversight group, including the following optional elements: For overweight and obese individuals, regular support groups for weight loss and prevention of weight regain. For all work site employees irrespective of weight, handouts and posted informational resources on healthy eating, monthly lunchtime seminars, and food sampling to facilitate healthy eating patterns for prevention of weight gain.

Basic online assessments on health and nutrition will be carried out at baseline (week 0) and 24 weeks in all work site employees willing to provide information. More detailed online and in-person assessments will be performed throughout the 24-week study period in the weight loss support group participants (intervention sites) and individuals intending to enroll in the support group (control sites).


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A
B: Arm Label: A: Study diet; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: B: Study diet plus Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: C: Study diet plus metformin and avandia; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Intervention Type: DRUG; Name: metformin and rosiglitazone; Assigned to Arm(s): A: Study diet, B: Study diet plus Metformin, C: Study diet plus metformin and avandia
C: Arm Label: New Nordic Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Arm Label: Average Danish Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Intervention Type: BEHAVIORAL; Name: Dietary intervention; Assigned to Arm(s): Average Danish Diet, New Nordic Diet
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Healthy Weight for Life Program
Brief Summary: This study is a randomized controlled pilot of a work site weight control intervention. The purpose of the pilot is to obtain preliminary data for future NIH submissions. Four work sites were identified through a multistage recruiting process. Work sites were randomized to either the intervention group, which will receive the intervention immediately following randomization or the control group which will receive a shortened intervention over a 1-month period, 6 months after the active intervention sites have completed their program. The intervention will consist of a variety of activities conducted over a 6 month period, that are overseen by a work site-Tufts oversight group, including the following optional elements: For overweight and obese individuals, regular support groups for weight loss and prevention of weight regain. For all work site employees irrespective of weight, handouts and posted informational resources on healthy eating, monthly lunchtime seminars, and food sampling to facilitate healthy eating patterns for prevention of weight gain.

Basic online assessments on health and nutrition will be carried out at baseline (week 0) and 24 weeks in all work site employees willing to provide information. More detailed online and in-person assessments will be performed throughout the 24-week study period in the weight loss support group participants (intervention sites) and individuals intending to enroll in the support group (control sites).


Options:
A: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
B: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group
D: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "A Comparison of the Efficacy of the Adductor-Canal-Blockade Versus the Femoral Nerve Block on Muscle Strength, Pain and Mobilization After Total Knee Arthroplasty: a Randomized Study
Brief Summary: The aim of this study is to investigate the efficacy of the Adductor-Canal-Blockade versus the Femoral Nerve Block on muscle strength, pain and mobilization after total knee arthroplasty. We hypothesize that the Adductor-Canal-Blockade has the same effect on pain and morphine consumption as the Femoral Nerve Block, but without the same reduction in quadriceps muscle strength.


Options:
A: Arm Label: Active FNB, placebo ACB; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine, Drug: Placebo | Arm Label: Active ACB, placebo FNB; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine, Drug: Placebo | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Active ACB, placebo FNB, Active FNB, placebo ACB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active ACB, placebo FNB, Active FNB, placebo ACB
B: Arm Label: Saline boluses in nerve catheter; Type: SHAM_COMPARATOR; Interventions: Procedure: Saline boluses in nerve catheter | Arm Label: Continuous saphenous nerve block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: continuous saphenous nerve block | Intervention Type: PROCEDURE; Name: continuous saphenous nerve block; Assigned to Arm(s): Continuous saphenous nerve block | Intervention Type: PROCEDURE; Name: Saline boluses in nerve catheter; Assigned to Arm(s): Saline boluses in nerve catheter
C: Arm Label: Adductor Canal Block:; Type: EXPERIMENTAL; Interventions: Procedure: Adductor Canal Block, Bupivacaine | Arm Label: Femoral Nerve Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral Nerve Block, Bupivacaine | Intervention Type: PROCEDURE; Name: Adductor Canal Block, Bupivacaine; Assigned to Arm(s): Adductor Canal Block: | Intervention Type: PROCEDURE; Name: Femoral Nerve Block, Bupivacaine; Assigned to Arm(s): Femoral Nerve Block
D: Arm Label: Adductor-Canal-Blockade; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade | Arm Label: Femoral Nerve Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral Nerve Block | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade; Assigned to Arm(s): Adductor-Canal-Blockade | Intervention Type: PROCEDURE; Name: Femoral Nerve Block; Assigned to Arm(s): Femoral Nerve Block

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Brief Summary: This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.


Options:
A: Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 0.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 10 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 3 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 0.5 mg BID | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CP-690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg BID
D: Arm Label: CP-690,550 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,500 5 mg | Arm Label: CP-690,550 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 10 mg | Intervention Type: DRUG; Name: CP-690,500 5 mg; Assigned to Arm(s): CP-690,550 5 mg | Intervention Type: DRUG; Name: CP-690,550 10 mg; Assigned to Arm(s): CP-690,550 10 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extracorporeal Membrane Oxygenation(ECMO) for Severe Acute Respiratory Distress Syndrome (ARDS)
Brief Summary: This international multicenter, randomized, open trial will evaluate the impact of Extracorporeal Membrane Oxygenation (ECMO), instituted early after the diagnosis of acute respiratory distress syndrome (ARDS) not evolving favorably after 3-6 hours under optimal ventilatory management and maximum medical treatment, on the morbidity and mortality associated with this disease.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: lung protective ventilation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: lung protective ventilation | Intervention Type: OTHER; Name: lung protective ventilation; Assigned to Arm(s): 1, 2
B: Arm Label: ECMO arm; Type: EXPERIMENTAL; Interventions: Device: ECMO (Quadrox®, Jostra®, Maquet®) | Arm Label: conventional arm; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional care | Intervention Type: DEVICE; Name: ECMO (Quadrox®, Jostra®, Maquet®); Assigned to Arm(s): ECMO arm | Intervention Type: OTHER; Name: conventional care; Assigned to Arm(s): conventional arm
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECCO2R to enable lower tidal volume mechanical ventilation; Type: EXPERIMENTAL; Interventions: Device: VV-ECCO2R to enable lower tidal volume mechanical ventilation | Intervention Type: DEVICE; Name: VV-ECCO2R to enable lower tidal volume mechanical ventilation; Assigned to Arm(s): ECCO2R to enable lower tidal volume mechanical ventilation
D: Arm Label: One Group; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based Formulas
Brief Summary: This clinical trial will compare the amount of fatty acids in whole blood of babies fed one of two study formulas for 4 months.


Options:
A: Arm Label: Experimental Infant Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Infant Formula | Intervention Type: OTHER; Name: Experimental Infant Formula; Assigned to Arm(s): Experimental Infant Formula
B: Arm Label: Arm 1 - AA Formula with DHA and ARA; Type: OTHER; Interventions: Other: Amino Acid-based Formula with high DHA and ARA | Arm Label: Arm 2 - AA Formula with alternative levels of DHA and ARA; Type: OTHER; Interventions: Other: Amino Acid-based Formula with lower DHA and ARA | Intervention Type: OTHER; Name: Amino Acid-based Formula with high DHA and ARA; Assigned to Arm(s): Arm 1 - AA Formula with DHA and ARA | Intervention Type: OTHER; Name: Amino Acid-based Formula with lower DHA and ARA; Assigned to Arm(s): Arm 2 - AA Formula with alternative levels of DHA and ARA
C: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula
D: Arm Label: Standard amino acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amino acids | Arm Label: High amino acids; Type: EXPERIMENTAL; Interventions: Drug: Amino acids | Intervention Type: DRUG; Name: Amino acids; Assigned to Arm(s): High amino acids, Standard amino acids

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Bispectral Index (BIS) Monitoring on Faster Recovery Time and Analgesic Consumption in Abdominal Surgery Patients
Brief Summary: Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. The aim of the study was to investigate the effect of BIS monitoring on extubation and recovery time, and intraoperative anesthesia consumption.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
B: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
C: Arm Label: anesthesia monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Arm Label: no bispectral index monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Intervention Type: DEVICE; Name: bispectral index monitoring; Assigned to Arm(s): anesthesia monitoring, no bispectral index monitoring
D: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Bispectral Index (BIS) Monitoring on Faster Recovery Time and Analgesic Consumption in Abdominal Surgery Patients
Brief Summary: Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. The aim of the study was to investigate the effect of BIS monitoring on extubation and recovery time, and intraoperative anesthesia consumption.


Options:
A: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
B: Arm Label: anesthesia monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Arm Label: no bispectral index monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Intervention Type: DEVICE; Name: bispectral index monitoring; Assigned to Arm(s): anesthesia monitoring, no bispectral index monitoring
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol, midazolam, fentanyl | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol, midazolam, fentanyl | Intervention Type: DRUG; Name: Propofol, midazolam, fentanyl; Assigned to Arm(s): 1, 2
D: N/A

Answer: B